4,960 Shares in Natera, Inc. $NTRA Purchased by Mangrove Partners IM LLC

Mangrove Partners IM LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 4,960 shares of the medical research company’s stock, valued at approximately $1,136,000.

A number of other large investors have also added to or reduced their stakes in the stock. Horizon Investments LLC increased its holdings in Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares during the last quarter. Sound Income Strategies LLC increased its holdings in Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after buying an additional 45 shares during the last quarter. Savvy Advisors Inc. increased its stake in shares of Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH increased its stake in shares of Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH increased its stake in shares of Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after purchasing an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 3,405 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the transaction, the insider directly owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 159,378 shares of company stock valued at $34,640,860 in the last quarter. 5.05% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. Robert W. Baird set a $265.00 target price on shares of Natera in a research note on Friday, May 8th. William Blair initiated coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Wolfe Research initiated coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley reduced their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Trading Up 1.4%

Shares of NASDAQ:NTRA opened at $220.11 on Wednesday. The company has a 50 day moving average of $206.92 and a 200 day moving average of $215.57. The stock has a market cap of $31.52 billion, a P/E ratio of -135.04 and a beta of 1.56. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.